The US Supreme Court shouldn’t review a ruling that allowed a lawsuit over drugmakers’ alleged financial ties to a series of terrorist attacks in Iraq, plaintiffs said.
A panel for the US Court of Appeals for the D.C. Circuit ruled in 2022 that the plaintiffs — victims and their family members — had adequately accused the companies of assisting the terrorist group Jaysh al-Mahdi by selling their drugs to and bribing officials in the Iraqi Ministry of Health when the terrorist group controlled the ministry and used it as a base for attacks. The full appeals court backed that decision ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.